Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.
Press releases published on April 24, 2025
Finance Denmark selects SurePay for nation-wide Verification Of Payee services in Denmark
GlobeNewswire
·
April 24, 2025
UTRECHT, The Netherlands and COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Finance Denmark, the association representing banks, mortgage institutions and financial firms in Denmark, has selected SurePay to provide a national Verification Of Payee …
Finance Denmark selecciona a SurePay para ofrecer servicios de Verification Of Payee a nivel nacional en Dinamarca
GlobeNewswire
·
April 24, 2025
UTRECHT, Países Bajos y COPENHAGUE, Dinamarca, April 24, 2025 (GLOBE NEWSWIRE) -- Finance Denmark, la asociación que representa a los bancos, instituciones hipotecarias y empresas financieras de Dinamarca, ha seleccionado a SurePay para proporcionar un …
Einführung der Verification Of Payee im ersten Nicht-Euro-Land
GlobeNewswire
·
April 24, 2025
KOPENHAGEN, Dänemark und UTRECHT, Niederlande und HAMBURG, Deutschland, April 24, 2025 (GLOBE NEWSWIRE) -- Finance Denmark, ein dänischer Unternehmensverband für Banken, Hypothekeninstitute, Vermögensverwaltung, Wertpapierhandel und Investmentfonds, setzt …
Finance Denmark sélectionne SurePay pour fournir le service national de la Verification Of Payee au Danemark
GlobeNewswire
·
April 24, 2025
UTRECHT, Pays-Bas et COPENHAGUE, Danemark, 24 avr. 2025 (GLOBE NEWSWIRE) -- Finance Denmark, l'association représentant les banques, les établissements hypothécaires et les sociétés financières au Danemark, a choisi SurePay pour fournir un service national …
Finance Denmark kiest SurePay voor Verification Of Payee
GlobeNewswire
·
April 24, 2025
KOPENHAGEN, Denemarken en UTRECHT, Nederland, April 24, 2025 (GLOBE NEWSWIRE) -- Finance Denmark, de associatie van Deense banken, heeft SurePay geselecteerd als leverancier voor Verification Of Payee (VOP). De keuze maakt SurePay verantwoordelijk voor …
Omnea Named “Best Overall eProcurement Software” in 2025 FinTech Breakthrough Awards Program
GlobeNewswire
·
April 24, 2025
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- FinTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global FinTech market, today announced that Omnea, the procurement intake …
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
GlobeNewswire
·
April 24, 2025
Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate Phase 2b study Gosselies, Belgium, 24 …
Bioxodes annonce des données intermédiaires positives pour son essai de phase 2a portant sur BIOX-101 dans le traitement de l’AVC hémorragique
GlobeNewswire
·
April 24, 2025
Le critère d’évaluation principal a été atteint, aucun événement indésirable grave associé au médicament n’a été rapporté L’évolution du volume de l’hématome et de l’œdème est favorable Le recrutement des patients a été arrêté plus tôt que prévu en raison …
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
GlobeNewswire
·
April 24, 2025
Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated with elafibranor versus placebo showed …
Les dernières données sur l’élafibranor démontrent un profil de tolérance favorable et une efficacité significative dans la CSP, une deuxième indication dans les maladies rares du foie
GlobeNewswire
·
April 24, 2025
L’élafibranor a montré un profil de tolérance favorable et a démontré une efficacité en termes de relation dose-effet sur 12 semaines chez des patients atteints de CSP, une maladie rare du foie pour laquelle il n’existe actuellement aucune option de …
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
GlobeNewswire
·
April 24, 2025
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO Dupixent sales were €3.5 billion, up 20. …
Communiqué de presse : Sanofi : forte performance au T1 et confirmation des perspectives pour 2025
GlobeNewswire
·
April 24, 2025
Sanofi : forte performance au T1 et confirmation des perspectives pour 2025 Paris, le 24 avril 2025 Ventes du T1 en progression de 9,7 % à TCC1 et BNPA2 des activités de 1,79 euro Les ventes des nouveaux lancements pharmaceutiques atteignent 0,8 milliard d …
Starke Verkäufe von Cresemba® (Isavuconazol) in Japan lösen zweite Umsatzmeilensteinzahlung von Asahi Kasei Pharma an Basilea aus
GlobeNewswire
·
April 24, 2025
Allschwil, 24. April 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, …
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
GlobeNewswire
·
April 24, 2025
Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of …
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
GlobeNewswire
·
April 24, 2025
Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPREME-2 trial investigates the efficacy and safety of …
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
GlobeNewswire
·
April 24, 2025
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will …
Verses AI Inc Announces Pricing of Public Offering of Units
GlobeNewswire
·
April 24, 2025
VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Verses AI Inc. (CBOE: VERS) (OTCQB: VRSSD) (“Verses” or the “Company”) is pleased to announce the pricing of its previously announced public offering (the “Offering”), of 2,750,000 units of …
Grupo Aeroportuario del Pacifico Announces Filing of 2024 Annual Report and Form 20-F
GlobeNewswire
·
April 24, 2025
GUADALAJARA, Mexico, April 24, 2025 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) today announced the filing of its annual report, corresponding to the year ended December 31, 2024, to …
Snail, Inc. 独立品牌 Wandering Wizards 获 Whispers of West Grove 发行权
GlobeNewswire
·
April 24, 2025
卡尔弗城，加利福尼亚州, April 24, 2025 (GLOBE NEWSWIRE) -- 作为全球领先的互动数字娱乐领域独立开发和发行商，Snail, Inc. (Nasdaq: SNAL，以下简称“Snail Games”或“公司”) 正式宣布，其旗下独立游戏发行部门 Wandering Wizard 已获得 Whispers of West Grove 的发行权，这是一款由 NVNT 工作室开发且即将推出的心理惊悚类恐游。 该游戏将在 Steam 发布，扩大了 Wandering Wizard …
Snail, Inc. 旗下獨立遊戲商 Wandering Wizards 獲《Whispers of West Grove》出版權
GlobeNewswire
·
April 24, 2025
卡爾弗城，加州, April 24, 2025 (GLOBE NEWSWIRE) -- 全球領先的互動數碼娛樂獨立開發商和發行商 Snail, Inc. (Nasdaq: Snal) (「Snail Games」或「公司」)，正式宣布其獨立發行商 Wandering Wizard 已獲由 NVNT Studios 開發、即將推出的心理恐怖遊戲《Whispers of West Grove》的出版權。 該遊戲將在 Steam 上發行，擴展了 Wandering Wizard …